Precision Biosciences (DTIL)
NASDAQ:DTIL
Want to see DTIL full AI Analyst Report?
Top Page
Precision BioSciences
(NASDAQ:DTIL)
Select Model
Select Model
Rating:43Neutral
Price Target:
$6.00
▼(-23.86% Downside)
Action:Reiterated
Date:06/17/26
The score is primarily constrained by weak financial performance (sizeable losses and continued negative operating/free cash flow). Technical indicators also point to weak near-term momentum. Offsetting factors include positive corporate developments (encouraging clinical updates and improved debt maturity profile), but they are not enough to overcome the current profitability and cash-burn profile.
Positive Factors
Proprietary ARCUS platform & partnerships
Owning a proprietary genome-editing platform with an established history of collaborations provides durable commercial optionality: partnership revenue, milestone streams, and external validation reduce binary single-product risk and enable scaling via partners while company advances internal programs.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means ongoing reliance on external financing. Over a multi‑month horizon this increases dilution risk, constrains discretionary R&D investment timing, and forces management to prioritize near-term funding over long-term strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ARCUS platform & partnerships
Owning a proprietary genome-editing platform with an established history of collaborations provides durable commercial optionality: partnership revenue, milestone streams, and external validation reduce binary single-product risk and enable scaling via partners while company advances internal programs.
Read all positive factors
Precision BioSciences (DTIL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$160.23M
Dividend YieldN/A
Average Volume (3M)326.03K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth-11.87%
EPS Growth-86.91%
CountryUS
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.35
Shares Outstanding25,802,246
10 Day Avg. Volume367,889
30 Day Avg. Volume326,033
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.06
Enterprise Value/Revenue0.22
Enterprise Value/Gross Profit0.23
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$32.25Price Target Upside309.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.62
Revenue Forecast (FY)$20.48M
Precision BioSciences Business Overview & Revenue Model
Company Description
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary gen...
How the Company Makes Money
Precision BioSciences generates revenue primarily through collaboration and licensing arrangements tied to its ARCUS genome editing platform rather than from product sales (as it has been a clinical-stage company). These arrangements typically inc...
Precision BioSciences Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.07M | 34.26M | 68.70M | 48.73M | 25.10M | 115.53M |
| Gross Profit | 43.70M | 31.51M | 68.70M | 48.73M | 25.10M | 115.53M |
| EBITDA | -40.42M | -42.43M | 13.53M | -32.04M | -62.79M | -20.27M |
| Net Income | -44.48M | -46.61M | 7.17M | -61.32M | -111.64M | -30.60M |
Balance Sheet | ||||||
| Total Assets | 143.89M | 154.42M | 136.39M | 159.78M | 238.17M | 211.50M |
| Cash, Cash Equivalents and Short-Term Investments | 101.18M | 115.58M | 86.31M | 116.68M | 189.58M | 143.66M |
| Total Debt | 28.47M | 28.81M | 30.05M | 31.27M | 24.96M | 9.11M |
| Total Liabilities | 67.79M | 62.17M | 80.00M | 140.92M | 177.74M | 120.33M |
| Stockholders Equity | 76.10M | 92.25M | 56.39M | 18.86M | 60.43M | 91.17M |
Cash Flow | ||||||
| Free Cash Flow | -58.78M | -65.93M | -58.70M | -86.39M | -49.07M | -16.66M |
| Operating Cash Flow | -58.73M | -65.84M | -58.45M | -84.11M | -45.75M | -10.85M |
| Investing Cash Flow | -434.00K | -634.00K | -215.00K | 5.83M | -3.32M | -5.80M |
| Financing Cash Flow | 85.22M | 95.16M | 50.45M | 5.39M | 94.98M | 70.52M |
Precision BioSciences Technical Analysis
Neutral
7.88
Price Trends
7.10
Negative
5.96
Positive
5.63
Positive
Market Momentum
-0.25
Positive
42.50
Neutral
10.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Neutral. The current price of 7.88 is above the 20-day moving average (MA) of 6.73, above the 50-day MA of 7.10, and above the 200-day MA of 5.63, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 42.50 is Neutral, neither overbought nor oversold. The STOCH value of 10.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DTIL.
Precision BioSciences Risk Analysis
Precision BioSciences disclosed 75 risk factors in its most recent earnings report. Precision BioSciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precision BioSciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $65.06M | -0.75 | -64.43% | ― | ― | 9.80% | |
49 Neutral | $661.82M | -8.78 | -36.61% | ― | -75.91% | -173.33% | |
48 Neutral | $65.43M | -1.36 | -35.20% | ― | ― | 49.30% | |
47 Neutral | $75.81M | -0.77 | -80.35% | ― | ― | 27.27% | |
43 Neutral | $160.23M | -1.82 | -81.24% | ― | -11.87% | -86.91% |
* Healthcare Sector Average
DTIL
Precision BioSciences
6.31
1.61
34.26%
CTMX
CytomX Therapeutics
2.93
0.82
38.86%
ACET
Adicet Bio
7.76
-2.94
-27.50%
IMA
ImageneBio
5.45
-10.99
-66.85%
ACRV
Acrivon Therapeutics, Inc.
1.49
0.25
20.16%
Precision BioSciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Precision BioSciences Extends Term Loan Maturity to 2029
Positive
Jun 16, 2026
On June 10, 2026, Precision BioSciences, Inc. amended its existing loan and security agreement with Banc of California, entering into a first amendment that modifies the terms of its term loan facility. Under the revised agreement, the maturity da...
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Reports Promising New Hepatitis B Trial Data
Positive
May 27, 2026
On May 27, 2026, Precision BioSciences reported new and late-breaking clinical and biopsy data from its ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B, presented at the European Association for the Study of the Liver Congre...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Precision BioSciences Shareholders Approve Incentive Plan and Directors
Positive
May 26, 2026
On May 21, 2026, Precision BioSciences held its annual meeting of stockholders, where shareholders approved an amended and restated 2019 Incentive Award Plan that increases the pool of shares available for equity-based compensation by 3,800,000 sh...
Business Operations and StrategyProduct-Related Announcements
Precision BioSciences Highlights PBGENE-DMD Program and Trial
Positive
Mar 17, 2026
On March 17, 2026, Precision BioSciences hosted a live investor and key opinion leader webcast to provide an update on its PBGENE-DMD gene-editing program and the FUNCTION-DMD Phase 1/2 trial for Duchenne muscular dystrophy. Pediatric neurologist ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.